Get the Stockscreener App
39.25
0.36%
-0.14
Royalty Pharma Plc stock is traded at $39.25, with a volume of 1.09M.
It is down -0.36% in the last 24 hours and down -1.26% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$39.39
Open:
$39.39
24h Volume:
1.09M
Relative Volume:
0.30
Market Cap:
$16.77B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
17.09
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
+2.45%
1M Performance:
-1.26%
6M Performance:
+8.61%
1Y Performance:
+55.57%
1-Day Range:
$39.24
$39.50
1-Week Range:
$38.20
$39.50
52-Week Range:
$25.16
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
39.25 | 16.83B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Swedbank AB Acquires 42,800 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $767,600.00 in Stock - MarketBeat
Royalty Pharma Announces Planned Legal Leadership Transition - TipRanks
Royalty Pharma names McGivern as chief legal officer - StreetInsider
The Technical Signals Behind (RPRX) That Institutions Follow - Stock Traders Daily
Royalty Pharma Gains from MYQORZO FDA Approval - TradingView — Track All Markets
Royalty Pharma (NASDAQ:RPRX) EVP Sells $3,060,375.22 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 30,654 Shares of Stock - MarketBeat
Royalty Pharma : Q4 2025 Pre-Quarterly Results Communication - marketscreener.com
How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Royalty Pharma PLC $RPRX Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Dividend Watch: How Royalty Pharma plc stock compares to growth peers - Улправда
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 69,582 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares - MarketBeat
Royalty Pharma Insider Sold Shares Worth $766,420, According to a Recent SEC Filing - marketscreener.com
VP Urist Sells 20,000 ($766.4K) Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Nigeria
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln - MSN
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Shareholder Sandy Lamm LLC Files To Sell 160,000 Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal - Sahm
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - TipRanks
Nuvalent (NASDAQ: NUVL) notes Royalty Pharma deal, 1.5% royalty on two drugs - Stock Titan
Royalty Pharma stock rises after acquiring cancer drug royalties By Investing.com - Investing.com Nigeria
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - citybiz
Royalty Pharma stock rises after acquiring cancer drug royalties - Investing.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma acquires royalty interest in cancer drugs for $315 million By Investing.com - Investing.com India
Royalty Pharma acquires royalty interest in cancer drugs for $315 million - Investing.com
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma acquires drug royalty rights for up to $315 million - StreetInsider
Shareholder TPC RP EPA1 LLC Files To Sell 3,750 Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
Royalty Pharma (RPRX): Revisiting Valuation After Fresh Analyst Upgrades and Strengthening Buy-Side Consensus - Sahm
Squarepoint Ops LLC Makes New $9.85 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Buys 41,830 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat
TD Cowen Maintains Royalty Pharma (RPRX) Buy Recommendation - Nasdaq
TD Cowen raises Royalty Pharma stock price target on growth outlook By Investing.com - Investing.com South Africa
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com
TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus
TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider
First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $913,526.10 in Stock - MarketBeat
Royalty Pharma EVP Sells Over $1.6 Million in Shares - TradingView — Track All Markets
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):